SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Venus Concept Inc

Venus Concept (VERO) is trending following Madryn Asset Management's acquisition of a 91% stake, sparking widespread discussion about potential privatization or delisting to reduce operational costs. The community is sharply divided, with bulls anticipating a significant short squeeze fueled by the now extremely low public float. Conversely, skeptics caution against a "pump and dump" scenario and potential dilution or a lower buyout price as the company's long-term financials are scrutinized.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing significant momentum following recent international regulatory approvals for its Anktiva treatment and compelling updates from ongoing clinical trials, fueling widespread community optimism. The stock is seeing massive trading volume and a strong belief in an intensifying short squeeze, with many retail investors expressing conviction in the company's long-term potential to revolutionize cancer treatment.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is trending due to a landmark multi-year data center lease with Advanced Micro Devices, signaling a significant strategic pivot towards high-performance computing and AI infrastructure. This transformative deal is generating immense bullish sentiment within the community, validating Riot's strategic shift from Bitcoin mining and fueling expectations for further substantial partnerships.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is drawing significant attention following the announcement of a new 200 million share buyback program and substantial European defense procurements, including Leopard 2 tanks powered by its MTU engines. The community expresses strong bullish sentiment, anticipating robust upcoming earnings and the game-changing potential of its Small Modular Reactor (SMR) technology.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is trending due to significant selling pressure, with the community attributing much of the decline to ongoing insider share sales and impending lock-up expirations, leading to widespread investor frustration over post-IPO losses. However, amidst the bearish sentiment, some investors are buying dips, highlighting Figma's strong adoption as a core design tool, its market leadership, and strategic AI integrations as reasons for long-term confidence despite current market dynamics.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending due to multiple analyst downgrades and heightened concerns over AI-driven competition, including new offerings from Apple, impacting the broader software sector. While many express fear that AI will significantly disrupt Adobe's established creative suite and subscription model, others view the stock as deeply oversold given its strong fundamentals, consistent growth, and historically low valuation, anticipating a rebound as AI integration evolves.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is trending with high volatility and a notable price decline, which the community links to broader tech sector weakness and emerging competition in the advertising space from AI-related developments. Despite numerous recent analyst upgrades highlighting its AI-powered Axon platform and expanding e-commerce presence, investors are actively debating if the sell-off reflects overvaluation, market manipulation around options expiration, or sector-wide rotation. Many see the current dip as a strategic buying opportunity, betting on its strong fundamentals and anticipated performance.

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

ARS Pharmaceuticals Inc

ARS Pharmaceuticals (SPRY) is trending as its competitor, AQST, received an FDA deficiency letter, potentially solidifying Neffy's lead in the needle-free epinephrine market. The community is actively discussing a significant short squeeze opportunity for SPRY, fueled by high short interest and recent global approvals, alongside its promising pipeline expansion into new indications like urticaria treatment.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian ($TEAM) is undergoing a severe, broad-based sell-off across the software sector, pushing its valuation to multi-year lows despite recent strong earnings, raised guidance, and a new share buyback program. Community discussion is split between viewing this as an "unreal opportunity" for a significant rebound given oversold conditions, or fearing continued weakness due to the ongoing "software is dead" narrative, concerns about AI integration, and consistent insider selling.

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. It operates through the Biotechnology and Technology segments. The Biotechnology segment is involved in developing biotechnology product pipelines. The Technology segment relates to acquiring technology assets to support and enhance operational capabilities through advanced technologies. The company was founded in 2017 and is headquartered in Wexford, PA.

Coeptis Therapeutics Holdings Inc

Coeptis Therapeutics Inc

Coeptis Therapeutics is trending amidst widespread anticipation for its imminent merger with Z Squared, a Dogecoin and Litecoin mining company, with a crucial shareholder vote approaching. The community is actively discussing the potential for a substantial revaluation and a significant upside, as the company pivots from biotech to digital asset mining with its value increasingly linked to crypto performance. Many are watching for a potential short squeeze, despite recent low trading volume attributed to short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arcturus Therapeutics Maps Near-Term Milestones for CF mRNA Therapy, ARCT-810 at J.P. Morgan Conference

Arcturus Therapeutics (NASDAQ:ARCT) CEO and President Joe Payne outlined the company's current focus on messenger RNA (mRNA) therapeutics, emphasizing a leaner operating profile and a near-term set...

Arcturus Therapeutics (NASDAQ:ARCT) Price Target Cut to $7.00 by Analysts at Citigroup

Citigroup cut their price objective on Arcturus Therapeutics from $9.00 to $7.00 and set a "neutral" rating for the company in a research report on Tuesday...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve brokerages that are currently covering the firm...

Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below Two Hundred Day Moving Average - Time to Sell?

Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Passes Below Two Hundred Day Moving Average - Should You Sell...

Arcturus Therapeutics (NASDAQ:ARCT) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Arcturus Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve ratings firms that are currently covering the...

ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know

Arcturus Therapeutics' stock slides 59%, primarily due to mixed interim results from the phase II study of its investigational inhaled cystic fibrosis therapy, ARCT-032.

Arcturus Therapeutics (NASDAQ:ARCT) Shares Pass Below 200 Day Moving Average - Should You Sell?

Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Passes Below 200-Day Moving Average - Here's Why...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twelve research firms that are currently covering the stock, MarketBeat...

Wall Street Zen Upgrades Arcturus Therapeutics (NASDAQ:ARCT) to "Hold"

Wall Street Zen upgraded shares of Arcturus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.79	--	--	N/A
Q3 '25	-$0.90	-$0.49	45.49%	BEAT
Q2 '25	-$0.89	-$0.34	61.87%	BEAT
Q1 '25	-$1.18	-$0.52	55.85%	BEAT
Q4 '24	-$0.55	-$1.11	-102.39%	MISSED

ARCT
Arcturus Therapeutics Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ARCT News

ARCTArcturus Therapeutics Holdings Inc